|
James Tcheng,
MD
Dr. James Tcheng is an
Associate Professor of Medicine at the Duke Clinical Research Institute
and the Duke University Health System in Durham, North Carolina,
USA. He attended medical school at Johns Hopkins University and
completed internship and residency at Barnes Hospital in St. Louis,
MO. He attended Duke University for cardiology fellowship, and was
appointed to the faculty of Duke in 1988.
Dr. Tcheng is a practicing
interventional cardiologist who has performed over 2,500 therapeutic
angioplasty procedures. He has expertise in the study and application
of antiplatelet and antithrombin therapeutics, design and conduct
of clinical trials, engineering of coronary angioplasty systems,
and computer database and networking technologies. His research
interests have focused on several areas, including direct angioplasty
and stenting in acute myocardial infarction, excimer laser angioplasty
in cardiovascular disease, the platelet glycoprotein IIb/IIIa inhibitors
in coronary intervention and the acute coronary syndromes, and the
newer antithrombin agents in vascular disease. He has been the principal
investigator or co-principal investigator of a number of major clinical
trials, including the PAR and CADILLAC trials of direct angioplasty
during acute myocardial infarction, the EPIC, EPILOG, PROLOG, EPISTENT,
and R3 trials of the platelet inhibitor abciximab (ReoPro), the
IMPACT, IMPACT II, PRIDE, and ESPRIT trials of eptifibatide (Integrilin),
and the LARS study of the excimer laser in the treatment of in-stent
restenosis.
|
